- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04557813
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion (REALTRK)
Registry for Molecular Testing, Treatment and Outcome of Patients With Locally Advanced or Metastatic Solid Tumors Harboring a Fusion of NTRK1, NTRK2 or NTRK3
Study Overview
Status
Conditions
Detailed Description
The REALTRK registry will provide data on treatment reality of patients with locally advanced or metastatic solid tumors harboring NTRK1, NTRK2 or NTRK3 gene fusions, thereby generating real world evidence. It will identify factors that influence treatment decisions after receiving the diagnosis of a NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive cancer. All treatment lines administered before and after the molecular diagnosis of a NTRK fusion-positive cancer, irrespective of the type of antineoplastic treatment, will be documented. Data will be assessed at least 36 months per patient (i.e. until 36 months after inclusion of the last patient in the study). This approach will allow a description of TRK fusion protein-targeted therapies and other therapy strategies regarding effectiveness and disease-related symptomology within the limitations of non-randomized studies in terms of comparative analyses. Intra-individual and inter-individual comparisons (for the latter, provided that a sufficient number of patients with a NTRK fusion-positive cancer are not treated with a TRK inhibitor) could be performed.
The associated biomarker profiling module of the REALTRK registry will aim to set up a decentralized biobank for future research on molecular alterations.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Beate Niemeier, Dr.
- Phone Number: +49/76115242
- Email: realtrk@iomedico.com
Study Locations
-
-
-
Berlin, Germany, 10707
- Onkologische Schwerpunktpraxis Kurfürstendamm
-
Frankfurt, Germany, 60389
- Centrum fur Hamatologie und Onkologie Bethanien
-
Freiburg, Germany, 79110
- Praxis für interdisziplinäre Onkologie & Hämatologie
-
Hamburg, Germany, 22763
- Asklepios Klinik Altona
-
Hannover, Germany, 30161
- Onkologische Schwerpunktpraxis
-
Hannover, Germany, 30625
- Gemeinschaftspraxis
-
Heilbronn, Germany, 74078
- SLK Kliniken Heilbronn Klinik für Innere Medizin III
-
Kempten, Germany, 87439
- Klinikum Kempten
-
Köln, Germany, 50674
- PIOH - Praxis Internistische Onkologie und Hämatologie
-
Landsberg, Germany, 86899
- Asklepios MVZ Bayern, Schwerpunkt Hämatologie/Onkologie
-
Lübeck, Germany, 23552
- Onkologische Praxis am Marien-Krankenhaus
-
Mönchengladbach, Germany, 41066
- Praxis für Onkologie
-
München, Germany, 81675
- Klinikum rechts der Isar der TUM Innere Medizin II
-
Münster, Germany, 48149
- Universitätsklinikum Münster, Medizinische Klinik A
-
Neuss, Germany, 41462
- TZN - Tumorzentrum Niederrhein GmbH
-
Ravensburg, Germany, 88212
- Studienzentrum Onkologie Ravensburg
-
Recklinghausen, Germany, 45659
- Praxis und Tagesklinik für Onkologie und Hämatologie
-
Rosenheim, Germany, 83022
- Klinikum Rosenheim
-
Schorndorf, Germany, 73614
- Zentrum Ambulante Onkologie
-
Soest, Germany, 59494
- MVZ Kloster Paradiese GbR
-
Ulm, Germany, 89073
- MVZ für Hämatologie und Onkologie
-
Villingen-Schwenningen, Germany, 78052
- Onkologie Schwarzwald-Alb
-
-
-
-
-
Basel, Switzerland, 4031
- Universitatsspital Basel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Locally advanced or metastatic solid tumor with a documented NTRK gene fusion, based on a validated assay (according to current ESMO recommendations), or the provision of tumor material for central retesting
- Molecular pathology or molecular diagnostics report with details on NTRK gene fusion testing must be available
- Aged ≥ 18 years
- Signed and dated informed consent form (ICF) (only if patient is alive at time of data entry into the project; not applicable for inclusion of deceased patients' data)
Exclusion Criteria:
- Treatment with a TRK inhibitor prior to Sept 19th, 2019 (Germany) or May 28th, 2020 (Switzerland)
- Participation in a clinical trial with a TRK inhibitor before or at enrolment (liv-ing patients) or before inclusion (deceased patients)
- Deceased patients who have explicitly contradicted further use of data
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
IC before start of any treatment
Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer.
All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
|
IC after start of any treatment
IC after start of any treatment after diagnosis of NTRK fusion-positive cancer.
Data after study inclusion are collected prospectively and retrospectively.
|
Deceased patients
Patients deceased prior to study inclusion (no IC required).
All data are collected retrospectively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 36 months
|
Proportion of patients with CR or PR as best response
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient and disease characteristics
Time Frame: 36 months
|
Descriptive summary of demographics, patient and disease characteristics
|
36 months
|
Test methods used for diagnosis of a NTRK fusion-positive cancer
Time Frame: Day 1
|
Description of test methods used for diagnosis of a NTRK fusion-positive cancer and results thereof
|
Day 1
|
Physician-reported factors affecting decision to test for NTRK fusion and treatment decision
Time Frame: Day 1
|
Description of physician-reported factors affecting decision to test for NTRK fusion and treatment decision making after diagnosis of NTRK gene fusion
|
Day 1
|
Treatment reality after diagnosis of NTRK gene fusion
Time Frame: 36 months
|
Description of all treatment lines given to the patient after diagnosis of NTRK gene fusion including: Type of treatment (Systemic TRK inhibitor treatments or Non-TRK inhibitor treatments), treatment duration, dosing, treatment modifications and reasons thereof, reasons for end of treatment.
|
36 months
|
Safety of TRK inhibitor treatments
Time Frame: 36 months
|
Treatment-emergent AEs (i.e., AEs which occurred during a specific TRK inhibitor treatment and in the respective survival FU) will be calculated per patient (absolute and relative frequencies) and case-based (absolute frequencies). The occurrence of any (S)AE will be displayed overall and per CTCAE grade. Adverse drug reactions (ADRs) and AESIs will be displayed accordingly. Incidence of AEs (MedDRA Preferred Term (PT) by System Organ Class (SOC)) will be calculated accordingly for each type of AE/ADR. |
36 months
|
Physician-reported evaluation of TRK inhibitor therapy
Time Frame: Day 1
|
Description of physician-reported evaluation of TRK inhibitor therapy
|
Day 1
|
Disease-related symptoms
Time Frame: 36 months
|
Description of courses of disease-related symptoms (weight loss, ECOG) after diagnosis of NTRK gene fusion (Only for patients of inclusion group I)
|
36 months
|
Disease control rate
Time Frame: 36 months
|
Proportion of patients with CR, PR or SD as best response
|
36 months
|
Time to Response
Time Frame: 36 months
|
Time from start of treatment to the first objective tumor response (e.g., tumor shrinkage of ≥30%) observed for patients who achieved a CR or PR
|
36 months
|
Duration of Response
Time Frame: 36 months
|
Time from documentation of tumor response to disease progression or death from any cause
|
36 months
|
Progression-free survival
Time Frame: 36 months
|
Time from start of treatment until disease progression or death
|
36 months
|
Overall Survival
Time Frame: 36 months
|
Time from start of treatment until death of any cause
|
36 months
|
PFS ratio
Time Frame: 36 months
|
ratio of PFS of the first treatment line with a TRK inhibitor to time to progression (TTP) in the preceding treatment line without a TRK inhibitor
|
36 months
|
Event-free survival
Time Frame: 36 months
|
Time from start of treatment until PD or death
|
36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Benjamin Kasenda, PD Dr. Dr., Universitätsspital Basel, Petersgraben 4, 4031 Basel, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IOM-040444
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NTRK Family Gene Mutation
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; Applied Health Research Centre; Takeda Canada, Inc.; Programs...RecruitingCancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene MutationCanada
-
Tianjin Medical University Second HospitalRecruitingSolid Tumor | FGF Receptor Gene Mutation | FGF Amplification | FGF Receptor Gene Family Rearrangement | FGF Receptor Gene TranslocationChina
-
Hoffmann-La RocheNo longer availableCancers With NTRK, ROS1, or ALK Gene FusionsUnited States
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
Rabin Medical CenterUnknownBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditionsUnited States